BPC-157 vs Uroguanylin
Side-by-Side Comparison
| Attribute | Bpc 157 | Uroguanylin |
|---|---|---|
| Category | Healing & Recovery | GI / Metabolic |
| Mechanism | BPC-157 acts through multiple overlapping pathways. It promotes angiogenesis by upregulating VEGFR2 and VEGF expression, and activates nitric oxide synthesis via the Src kinase-caveolin-1 pathway and... | Uroguanylin binds to GC-C receptors on the luminal surface of intestinal epithelial cells, stimulating intracellular cGMP production. |
| Evidence Rating | C — Phase I–II Clinical Trials | D — Preclinical (for uroguanylin itself) / A for GC-C pathway |
| Clinical Status | Research-only / No approved human indication. Phase I oral safety trial completed; Phase II UC trial underway. | Preclinical as a therapeutic. GC-C agonist drugs (linaclotide, plecanatide) are FDA-approved for IBS-C and chronic constipation. |
| Safety Profile | No completed randomized controlled human clinical trials for safety assessment; Preclinical safety studies across multiple species found no toxic or lethal dose thresholds at ranges from 6 mcg/kg to 20 mg/kg; LD1 not achieved; no teratogenic, genotoxic, or anaphylactic effects in necropsy/histopathology | Linaclotide and plecanatide (related GC-C agonists) have established safety profiles from Phase 3 trials and post-marketing surveillance; Primary side effect of GC-C activation is diarrhea (dose-dependent) |
| Molecular Weight | ~1419.5 g/mol | ~1667 g/mol |
| Half-Life | ~15 min IV (animal data); oral activity persists 24+ hours | N/A |
Overview
BPC-157 and Uroguanylin are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
BPC-157 — Mechanism & Evidence
BPC-157 is a synthetic 15-amino-acid peptide (sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, MW ~1419.5 g/mol) derived from a protein found in human gastric juice. It has demonstrated robust regenerative and cytoprotective effects across hundreds of animal studies spanning tendon, ligament, muscle, bone, nerve, GI tract, and blood vessel healing. However, human clinical data is extremely limited — only three pilot studies have examined BPC-157 in humans as of 2025 (knee pain n=16, interstitial cystitis n=12, IV safety n=2). The FDA classifies it as Category 2, prohibiting compounding, and WADA bans its use in sports.
Key claims: Accelerates tendon and ligament healing; Heals gut lining and treats leaky gut; Reverses NSAID-induced GI damage.
Uroguanylin — Mechanism & Evidence
Uroguanylin is a 16-amino-acid intestinal peptide hormone that activates guanylate cyclase C (GC-C) receptors on intestinal epithelial cells. It regulates fluid and electrolyte transport, intestinal barrier function, and has emerging roles in satiety signaling and colorectal cancer prevention. The FDA-approved drug linaclotide (Linzess) is a synthetic GC-C agonist based on the same signaling pathway. Uroguanylin is being studied as a more physiological approach to GC-C activation.
Key claims: Regulates intestinal fluid secretion; May act as a satiety hormone; Protects against colorectal cancer.
Shared Research Applications
Both peptides are studied for: Gut Health.
BPC-157 is also researched for: Injury Recovery.
Uroguanylin is also researched for: Metabolic Health.
Safety Considerations
BPC-157: No completed randomized controlled human clinical trials for safety assessment Preclinical safety studies across multiple species found no toxic or lethal dose thresholds at ranges from 6 mcg/kg to 20 mg/kg; LD1 not achieved; no teratogenic, genotoxic, or anaphylactic effects in necropsy/histopathology FDA previously classified BPC-157 as Category 2 (significant safety concerns); removed from Category 2 on April 15, 2026. PCAC review pending July 2026 to determine compounding eligibility. FDA noted insufficient human safety data and potential immunogenicity risks.
Uroguanylin: Linaclotide and plecanatide (related GC-C agonists) have established safety profiles from Phase 3 trials and post-marketing surveillance Primary side effect of GC-C activation is diarrhea (dose-dependent) Uroguanylin itself has not been tested in human clinical trials as a standalone therapy
Related Products
Related Research News
BPC-157 Gut Health: Gastric Cytoprotection Studies
Research on BPC-157 began with gastric cytoprotection in the early 1990s, led by Sikiric and colleagues at the University of Zagreb. Studies show it protects against ethanol-induced lesions and NSAID damage in rat models, with effects linked to angiogenesis, prostaglandins, nitric oxide, and gut-brain signaling. This body of work highlights its stability for oral use and broad preclinical applications in GI models.
BPC-157 Shelf Life: Lyophilized vs Reconstituted Stability Guide
BPC-157 has a finite shelf life that varies by form and storage. Lyophilized powder lasts 12-18 months refrigerated or 24+ months frozen, while reconstituted solution holds for about 28 days under refrigeration. Factors like temperature, light, and handling influence stability, and researchers should watch for signs of degradation to ensure reliable results.
BPC-157 + TB-500 Peptide Blend: Research on Healing and Repair
The BPC-157 and TB-500 peptide blend draws attention in research for potential synergy in tissue repair, angiogenesis, and reducing inflammation. BPC-157, a 15-amino-acid synthetic peptide, interacts with growth factors in preclinical models. TB-500, a 43-amino-acid analog of Thymosin Beta-4, supports cell migration and regeneration. Studies explore their roles in wound healing, tendon recovery, and more.